Personalis (PSNL) Revenue & Revenue Breakdown
Personalis Revenue Highlights
Latest Revenue (Y)
$73.48M
Latest Revenue (Q)
$19.52M
Personalis Revenue by Period
Personalis Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $73.48M | 12.97% |
| 2022-12-31 | $65.05M | -23.92% |
| 2021-12-31 | $85.49M | 8.70% |
| 2020-12-31 | $78.65M | 20.61% |
| 2019-12-31 | $65.21M | 72.62% |
| 2018-12-31 | $37.77M | 302.15% |
| 2017-12-31 | $9.39M | - |
Personalis generated $73.48M in revenue during NA 2023, up 12.97% compared to the previous quarter, and up 194.53% compared to the same period a year ago.
Personalis Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $19.52M | -0.76% |
| 2023-12-31 | $19.68M | 7.83% |
| 2023-09-30 | $18.25M | 9.27% |
| 2023-06-30 | $16.70M | -11.46% |
| 2023-03-31 | $18.86M | 12.79% |
| 2022-12-31 | $16.72M | 12.55% |
| 2022-09-30 | $14.86M | -18.54% |
| 2022-06-30 | $18.24M | 19.79% |
| 2022-03-31 | $15.23M | -26.38% |
| 2021-12-31 | $20.68M | -7.09% |
| 2021-09-30 | $22.26M | 2.73% |
| 2021-06-30 | $21.67M | 3.78% |
| 2021-03-31 | $20.88M | 3.49% |
| 2020-12-31 | $20.18M | 1.82% |
| 2020-09-30 | $19.82M | 1.65% |
| 2020-06-30 | $19.50M | 1.74% |
| 2020-03-31 | $19.16M | 5.55% |
| 2019-12-31 | $18.15M | 5.84% |
| 2019-09-30 | $17.15M | 8.39% |
| 2019-06-30 | $15.82M | 12.43% |
| 2019-03-31 | $14.07M | 6.98% |
| 2018-12-31 | $13.16M | 12.90% |
| 2018-09-30 | $11.65M | 32.45% |
| 2018-06-30 | $8.80M | 111.31% |
| 2018-03-31 | $4.16M | - |
Personalis generated $19.52M in revenue during Q1 2024, up -0.76% compared to the previous quarter, and up 116.76% compared to the same period a year ago.
Personalis Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ILMN | Illumina | $4.50B | $1.08B |
| CRL | Charles River Laboratories | $4.13B | $1.03B |
| NTRA | Natera | $1.08B | $413.35M |
| MYGN | Myriad Genetics | $678.40M | $191.90M |
| GTH | Genetron | $650.71M | $201.32M |
| GH | Guardant Health | $563.95M | $177.24M |
| BNR | Burning Rock Biotech | $537.43M | $125.62M |
| CDNA | CareDx | $280.32M | $92.27M |
| TWST | Twist Bioscience | $245.11M | $81.46M |
| CSTL | Castle Biosciences | $219.79M | $87.00M |
| PSNL | Personalis | $73.48M | $19.52M |
| STIM | Neuronetics | $71.35M | $16.45M |
| DRIO | DarioHealth | $20.35M | $6.25M |
| SERA | Sera Prognostics | $306.00K | - |
PSNL Revenue FAQ
What is Personalis’s yearly revenue?
Personalis's yearly revenue for 2023 was $73.48M, representing an increase of 12.97% compared to 2022. The company's yearly revenue for 2022 was $65.05M, representing a decrease of -23.92% compared to 2021. PSNL's yearly revenue for 2021 was $85.49M, representing an increase of 8.70% compared to 2020.
What is Personalis’s quarterly revenue?
Personalis's quarterly revenue for Q1 2024 was $19.52M, a -0.76% decrease from the previous quarter (Q4 2023), and a 3.53% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $19.68M, a 7.83% increase from the previous quarter (Q3 2023), and a 17.66% increase year-over-year (Q4 2022). PSNL's quarterly revenue for Q3 2023 was $18.25M, a 9.27% increase from the previous quarter (Q2 2023), and a 22.81% increase year-over-year (Q3 2022).
What is Personalis’s revenue growth rate?
Personalis's revenue growth rate for the last 3 years (2021-2023) was -14.05%, and for the last 5 years (2019-2023) was 12.69%.